Boston Scientific Corporation (BSX)
| Previous close | 68.02 |
| Open | 68.32 |
| Bid | 68.41 x 800 |
| Ask | 68.42 x 800 |
| Day's range | 67.80 - 68.62 |
| 52-week range | 48.35 - 69.21 |
| Volume | |
| Avg. volume | 6,381,241 |
| Market cap | 100.556B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 63.93 |
| EPS (TTM) | 1.07 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 74.20 |
ZacksUnveiling Boston Scientific (BSX) Q1 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
BenzingaFDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
On Wednesday, Boston Scientific Corporation (NYSE:BSX) said it recalled Obsidio Embolic by issuing a correction. The FDA has identified this as a Class I recall, the most severe type of recall. An investigation determined that delivery of Obsidio Embolic using the aliquot technique, a commonly used delivery method in embolization procedures, for lower gastrointestinal (GI) bleeding embolization, implies a high risk of bowel ischemia. The most serious and the most common adverse health consequenc
- Reuters
UPDATE 1-FDA classifies recall of Boston Scientific device as 'most serious'
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's device used to block blood flow during excessive bleeding or hemorrhaging as "most serious". An investigation showed that Boston's device, Obsidio Embolic, when used with a specific technique posed a higher risk of bowel ischemia during procedures to stop gastrointestinal (GI) bleeding, the agency said. Bowel ischemia describes disorders that occur when blood flow to your intestines decrease, causing severe abdominal pain.
